Snow Storm Offers Sarepta Reprieve From FDA Advisory Committee
This article was originally published in The Pink Sheet Daily
Executive Summary
No make-up date announced after weather worries force postponement, but Sarepta now has more time to contemplate answers to FDA questions about its Duchenne muscular dystrophy candidate eteplirsen.
You may also be interested in...
BioMarin's Drisapersen 'Compete Response' Shows FDA Flexibility Still Limited
FDA wants another clinical trial for Duchenne muscular dystrophy treatment; focus moves to Sarepta's candidate, which gets committee review next week.
New OSP Director To Guide CDER-Wide IT Upgrades; System Enhancements Speed ANDA Assessments
Generic Drug Structured Assessment for Bioequivalence launched in 2023 and has been used in 40 ANDA reviews so far.
US FDA Hopes Food, Inspection Office Reorg Bolsters Innovative Clinical Trial Adoption
Ensuring inspectors understand the innovative trial designs in use before an inspection will be important to increasing industry confidence in their use, CDER Director Patrizia Cavazzoni said.